Among patients with later stage hepatocellular carcinoma (HCC), only 1–12% manifest obstructive jaundice as the initial complaint. Endoscopic retrograde biliary drainage (ERBD) and percutaneous transhepatic biliary drainage (PTBD) are the two main non-surgical treatment options for obstructive jaundice in patients with HCC. ERBD is usually the first-line treatment because of its low hemorrhage risk. Some have reported that the successful drainage rate ranges from 72 to 100%. Mean stent patency time and mean survival range from 1.0 to 15.9 and 2.8 to 12.3 months, respectively. PTBD is often an important second-line treatment when ERBD is impossible. With regard to materials, metallic stents offer the benefit of longer patency than plastic stents. The dominant effect of biliary drainage suggests that successful jaundice therapy could enhance anti-cancer treatment by increasing life expectancy, decreasing mortality, or both. We present an overview of the efficacy of endoscopic and percutaneous drainage for obstructive jaundice in patients with HCC who are not candidates for surgical resection and summarize the current indications and outcomes of reported clinical use.

Keywords:
Endoscopic retrograde biliary drainage, Endoscopic ultrasound-guided biliary drainage, Hepatocellular carcinoma, Obstructive jaundice, Percutaneous transhepatic biliary drainage
1.
Qin LX, Tang ZY: Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol 2003;9:385–391.
2.
Lee NW, Wong KP, Siu KF, Wong J: Cholangiography in hepatocellular carcinoma with obstructive jaundice. Clin Radiol 1984;35:119–123.
3.
Huang JF, Wang LY, Lin ZY, et al: Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:190–195.
4.
Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2–14.
5.
Lau WY, Leung JW, Li AKC: Management of hepatocellular carcinoma presenting as obstructive jaundice. Am J Surg 1990;160:280–282.
6.
Lai EC, Lau WY: Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J Surg 2006;76:631–636.
7.
Lau WY, Leow CK, Leung KL, Leung TW, Chan M, Yu SC: Cholangiographic features in the diagnosis and management of obstructive icteric type hepatocellular carcinoma. HPB Surg 2000;11:299–306.
8.
Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G: Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol 2005;184:207–211.
9.
Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1,000 cases. Cancer 2005;103:1201–1209.
10.
Banerjee B, Teplick SK: Nonsurgical management of primary cholangiocarcinoma. Retrospective analysis of 40 cases. Dig Dis Sci 1995;40:701–705.
11.
Matsueda K, Yamamoto H, Umeoka F, Ueki T, Matsumura T, Tezen T, Doi I: Effectiveness of endoscopic biliary drainage for unresectable hepatocellular carcinoma associated with obstructive jaundice. J Gastroenterol 2001;36:173–180.
12.
Higashizawa T, Tamada K, Tomiyama T, Wada S, Ohashi A, Satoh Y, Gotoh Y, Miyata T, Ido K, Sugano K: Biliary guidewire facilitates bile duct biopsy and endoscopic drainage. J Gastroenterol Hepatol 2002;17:332–336.
13.
Rerknimitr R, Attasaranya S, Kladchareon N, Mahachai V, Kullavanijaya P: Feasibility and complications of endoscopic biliary drainage in patients with malignant biliary obstruction at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2002;85(suppl 1):S48–S53.
14.
Ahmad J, Siqueira E, Martin J, Slivka A: Effectiveness of the Ultraflex Diamond stent for the palliation of malignant biliary obstruction. Endoscopy 2002;34:793–796.
15.
Al-Mofleh IA, Al-Rashed RS, Al-Amri SM, Al-Ghamdi AS, Al-Faleh FZ, Al-Freihi HM, Isnani AC: Malignant biliary strictures. Diagnosis and management. Saudi Med J 2003;24:1360–1363.
16.
Freeman ML, Overby C: Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 2003;58:41–49.
17.
Rerknimitr R, Kladcharoen N, Mahachai V, Kullavanijaya P: Result of endoscopic biliary drainage in hilar cholangiocarcinoma. J Clin Gastroenterol 2004;38:518–523.
18.
Singh V, Kapoor R, Solanki KK, Singh G, Verma GR, Sharma SC: Endoscopic intraluminal brachytherapy and metal stent in malignant hilar biliary obstruction: a pilot study. Liver Int 2007;27:347–352.
19.
Naitoh I, Ohara H, Nakazawa T, Ando T, Hayashi K, Okumura F, Okayama Y, Sano H, Kitajima Y, Hirai M, Ban T, Miyabe K, Ueno K, Yamashita H, Joh T: Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol 2009;24:552–557.
20.
Chahal P, Baron TH: Expandable metal stents for endoscopic bilateral stent-within-stent placement for malignant hilar biliary obstruction. Gastrointest Endosc 2010;71:195–199.
21.
Gerhardt T, Rings D, Höblinger A, Heller J, Sauerbruch T, Schepke M: Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol 2010;48:28–32.
22.
Kogure H, Isayama H, Nakai Y, Tsujino T, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Kawakubo K, Sasaki T, Hirano K, Sasahira N, Tada M, Omata M, Koike K: Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study. Surg Endosc 2011;25:463–467.
23.
Kanno Y, Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, Takasawa O, Kato Y, Koshita S, Yamashita Y, Ogawa T: Single-session endoscopic bilaterally-configured placement of metal stents for hilar malignant biliary obstruction. Dig Endosc 2011;23:91–96.
24.
Hwang JC, Kim JH, Lim SG, Kim SS, Yoo BM, Cho SW: Y-shaped endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: prospective long-term study. Scand J Gastroenterol 2011;46:326–332.
25.
Soderlund C, Linder S: Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006;63:986–995.
26.
Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C: A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:1–7.
27.
Born P, Rösch T, Triptrap A, Frimberger E, Allescher HD, Ott R, Weigert N, Lorenz R, Classen M: Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures. Scand J Gastroenterol 1998;33:544–549.
28.
Guo YX, Li YH, Chen Y, Chen PY, Luo PF, Li Y, Shan H, Jiang ZB: Percutaneous transhepatic metal versus plastic biliary stent in treating malignant biliary obstruction: a multiple center investigation. Hepatobiliary Pancreat Dis Int 2003;2:594–597.
29.
Speer AG, Cotton PB, Russell RC, Mason RR, Hatfield AR, Leung JW, MacRae KD, Houghton J, Lennon CA: Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57–62.
30.
Piñol V, Castells A, Bordas JM, Real MI, Llach J, Montañà X, Feu F, Navarro S: Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology 2002;225:27–34.
31.
Voegeli DR, Crummy AB, Weese JL: Percutaneous transhepatic cholangiography, drainage, and biopsy in patients with malignant biliary obstruction. An alternative to surgery. Am J Surg 1985;150:243–247.
32.
Hii MW, Gibson RN, Speer AG, Collier NA, Sherson N, Jardine C: Role of radiology in the treatment of malignant hilar biliary strictures. 2. Ten years of single-institution experience with percutaneous treatment. Australas Radiol 2003;47:393–403.
33.
Weber A, Gaa J, Rosca B, Born P, Neu B, Schmid RM, Prinz C: Complications of percutaneous transhepatic biliary drainage in patients with dilated and nondilated intrahepatic bile ducts. Eur J Radiol 2009;72:412–417.
34.
Tsuyuguchi T, Takada T, Kawarada Y, Nimura Y, Wada K, Nagino M, Mayumi T, Yoshida M, Miura F, Tanaka A, Yamashita Y, Hirota M, Hirata K, Yasuda H, Kimura Y, Strasberg S, Pitt H, Büchler MW, Neuhaus H, Belghiti J, de Santibanes E, Fan ST, Liau KH, Sachakul V: Techniques of biliary drainage for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:35–45.
35.
Cho HC, Lee JK, Lee KH, Lee KT, Paik S, Choo SW, Do YS, Choo IW: Are endoscopic or percutaneous biliary drainage effective for obstructive jaundice caused by hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2011;23:224–231.
36.
Wiersema MJ, Sandusky D, Carr R, Wiersema LM, Erdel WC, Frederick PK: Endosonography-guided cholangiopancreatography. Gastrointest Endosc 1996;43:102–106.
37.
Giovannini M, Moutardier V, Pesenti C, Bories E, Lelong B, Delpero JR: Endoscopic ultrasound-guided bilioduodenal anastomosis: a new technique for biliary drainage. Endoscopy 2001;33:898–900.
38.
Giovannini M, Dotti M, Bories E, Moutardier V, Pesenti C, Danisi C, Delpero JR: Hepaticogastrostomy by echo-endoscopy as a palliative treatment in a patient with metastatic biliary obstruction. Endoscopy 2003;35:1076–1078.
39.
Mallery S, Matlock J, Freeman ML: EUS-guided rendezvous drainage of obstructed biliary and pancreatic ducts: report of 6 cases. Gastrointest Endosc 2004;59:100–107.
40.
Kahaleh M, Wang P, Shami VM, Tokar J, Yeaton P: EUS-guided transhepatic cholangiography: report of 6 cases. Gastrointest Endosc 2005;61:307–313.
41.
Püspök A, Lomoschitz F, Dejaco C, Hejna M, Sautner T, Gangl A: Endoscopic ultrasound-guided therapy of benign and malignant biliary obstruction: a case series. Am J Gastroenterol 2005;100:1743–1747.
42.
Tarantino I, Barresi L, Fabbri C, Traina M: Endoscopic ultrasound-guided biliary drainage. World J Gastrointest Endosc 2012;4:306–311.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.